// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Obstetrical and perinatal complications in survivors of childhood, adolescent, and young adult cancer: A population-based study.

Alina Zgardau - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The association between breast density and HER2-positive breast cancer: a population-based case-control study.

Vivian Tan - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Understanding the treatment effect modification of mono- or combination PD-1/PD-L1 inhibitor therapies on survival outcomes in patients with metastatic renal cell carcinoma: What does the literature say?

Neha Sati - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.

Siamak Daneshmand - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Infigratinib

Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy.

Selina Wong - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreato-biliary malignancies

N/A

HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: To offer more? (aTTom) trial.

John Bartlett - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Tamoxifen

Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study.

Ambika Satija - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dabrafenib Mesylate

Clinical trials navigator: Patient-centered access to clinical trials.

Caroline M. Hamm - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.

Ravit Geva - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

naptumomab estafenatox

Effectiveness and Safety of rFVIIA in Paediatric Glanzmann Thrombasthenia Patients: Data From the International Glanzmann Thrombasthenia Registry

R. Zotz - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

rFVIIa

Number of sentinel lymph nodes (SLN) removed in breast cancer (BC) patients undergoing sentinel lymph node biopsy (SLNB) in the province of Saskatchewan, Canada. Real-world experience.

Tyrell Wess - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Measuring Limitations in Activities and Participation In Persons With Haemophilia: A Systematic Review Of Commonly Used Measurement Tools

M. Timmer - European Association for Haemophilia and Allied Disorders (EAHAD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Use of Twitter among cancer clinicians and researchers and the associations with scientific impact of its users and followers.

Winson Y. Cheung - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.

Laurence Albiges - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Phase II basket trial of olaparib and durvalumab in patients (pts) with isocitrate dehydrogenase (IDH) mutated solid tumors.

Eric Xueyu Chen - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Durvalumab

A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.

Wilson H. Miller - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Aaron Richard Hansen - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Real-world outcomes among patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in first-line setting.

Daniel Simmons - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

L-Tyrosine

Breast cancer in women aged 80 years and older: Clinical characteristics and treatment patterns according to biologic subtype.

Stephanie M Wong - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.

Adam D. Cohen - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved